Kalsiom

Executive Summary

Kalsiom is a French biotechnology startup founded in 2018 and headquartered in Brest, dedicated to developing first-in-class therapies for autoimmune inflammatory diseases with significant unmet medical need. The company leverages innovative biologic approaches to address conditions where current treatments are inadequate, aiming to provide safer and more effective options for patients. As a private, early-stage company, Kalsiom is focused on advancing its proprietary platform from research toward preclinical development, with the goal of identifying lead candidates capable of modulating key inflammatory pathways. The biotech landscape for autoimmune diseases is rapidly evolving, and Kalsiom's unique approach positions it to potentially capture value in a large and growing market. However, the company has not publicly disclosed specific pipeline details or funding milestones, and its current stage is likely preclinical. The team's expertise and strategic location in a vibrant French biotech hub may support future progress, but execution risks remain high at this early phase. With no disclosed partnerships or financing rounds, visibility into near-term catalysts is limited, underscoring the need for continued monitoring.

Upcoming Catalysts (preview)

• H2 2026Series A Financing Round60% success
• Q1 2027Lead Candidate Selection and IND-Enabling Studies50% success
• Q4 2026Preclinical Proof-of-Concept Data at Scientific Conference70% success